secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0001104659-25-016929
Event type: regulatory
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone Pharma provides corporate presentation ahead of March 27 PDUFA for CARDAMYST
--------------------------------------------------------------------------------

- NDA for CARDAMYST (etripamil) nasal spray remains under FDA review with PDUFA date of March 27, 2025.
- Presentation outlines potential commercial launch strategy, but product is not yet approved.
- Company actively preparing for launch pending FDA decision.
- Presentation used at investor meetings; available on company website.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465925016929/0001104659-25-016929-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465925016929/tm257508d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-016929

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer